Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027

Beam Therapeutics Inc.

First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.
CTA submitted for BEAM-302 in alpha-1 antitrypsin deficiency; trial initiation planned H1 2024.
IND for BEAM-301 in glycogen storage disease 1a on track for H1 2024.
Estimated cash, cash equivalents and marketable securities of $1.2B as of Dec 31, 2023, funding operations into 2027.
BEAM-201 CAR-T trial enrollment ongoing; initial clinical dataset expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.